Serpex Medical Receives 510(k) Clearance for Its Compass Steerable Needles
Serpex Medical has received 510(k) clearance from the FDA for its Compass Steerable Needles.
The product is a needle intended to provide precise access to lung nodules in the intrapulmonary region during biopsy.
“Precision is essential for confidence in diagnosing lung cancer, especially out in the lung periphery,” said Sasha Schrode, president and CEO of Serpex, in a statement.
One of the Santa Clara, Calif.-based company’s goals is to improve the diagnosis and treatment of lung cancer through the use of steerable instruments, said Serpex.